Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.

@article{Hillerdal2008TreatmentOM,
  title={Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.},
  author={Gunnar Hillerdal and Jens Benn Sorensen and Stein Sundstr{\"o}m and Anders Vikstr{\"o}m and Anders Hjerpe},
  journal={The clinical respiratory journal},
  year={2008},
  volume={2 2},
  pages={80-5}
}
INTRODUCTION Malignant pleural mesothelioma (MPM) has a poor prognosis and there is limited effect of treatment. Lately, pemetrexed and cisplatin have been established as the standard treatment. OBJECTIVES The present study was planned in 1998, when there was no standard treatment. Single-dose doxorubicine had, in small studies, accomplished remissions, and the Scandinavian Mesothelioma Groups therefore decided to test a liposomized form of this drug, which had shown limited toxicity but good… CONTINUE READING